Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2007 Dec;25(12):1444-54.
doi: 10.1038/nbt1367.

Genetic therapies against HIV

John J Rossi  1 , Carl H June, Donald B Kohn
Affiliations
Review

Genetic therapies against HIV

John J Rossi et al. Nat Biotechnol. 2007 Dec.

Abstract

Highly active antiretroviral therapy prolongs the life of HIV-infected individuals, but it requires lifelong treatment and results in cumulative toxicities and viral-escape mutants. Gene therapy offers the promise of preventing progressive HIV infection by sustained interference with viral replication in the absence of chronic chemotherapy. Gene-targeting strategies are being developed with RNA-based agents, such as ribozymes, antisense, RNA aptamers and small interfering RNA, and protein-based agents, such as the mutant HIV Rev protein M10, fusion inhibitors and zinc-finger nucleases. Recent advances in T-cell-based strategies include gene-modified HIV-resistant T cells, lentiviral gene delivery, CD8(+) T cells, T bodies and engineered T-cell receptors. HIV-resistant hematopoietic stem cells have the potential to protect all cell types susceptible to HIV infection. The emergence of viral resistance can be addressed by therapies that use combinations of genetic agents and that inhibit both viral and host targets. Many of these strategies are being tested in ongoing and planned clinical trials.

PubMed Disclaimer

Conflict of interest statement

COMPETING INTERESTS STATEMENT

The authors declare competing financial interests: details accompany the full-text HTML version of the paper at http://www.nature.com/naturebiotechnology/.

Figures

Figure 1
Figure 1
HIV life cycle. (1) HIV binds to CD4 and co-receptors CCR5 and CXCR4 and is internalized. (2) Uncoating of virus. (3) Reverse transcription. (4) Integration into host chromosomal DNA. (5) Expression of early viral proteins from multiply spliced mRNAs. (6) Expression of late mRNAs encoding the structural proteins Env, Gag, Pol and integrase. (7) Packaging of unspliced genomic RNA and release of viral particles.
Figure 2
Figure 2
Inhibitory agents used in HIV hematopoietic cell gene therapy trials.
Figure 3
Figure 3
Adoptive immunotherapy strategies with gene-modified T cells and HS cells. Gene transfer approaches have tested engineered T cells and HS cells. Lymphodepletion enhances engraftment of both cell types. Other strategies under consideration include the use of common lymphoid progenitor cells (CLPs). PBMC, peripheral blood mononuclear cell.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Deeks SG. Antiretroviral treatment of HIV infected adults. Br Med J. 2006;332:1489. - PMC - PubMed
    1. Phillips AN, Gazzard BG, Clumeck N, Losso MH, Lundgren JD. When should antiretroviral therapy for HIV be started? Br Med J. 2007;334:76–78. - PMC - PubMed
    1. Sarver N, et al. Ribozymes as potential anti-HIV-1 therapeutic agents. Science. 1990;247:1222–1225. - PubMed
    1. Michienzi A, et al. RNA-mediated inhibition of HIV in a gene therapy setting. Ann NY Acad Sci. 2003;1002:63–71. - PubMed
    1. Ngok FK, et al. Clinical gene therapy research utilizing ribozymes: application to the treatment of HIV/AIDS. Methods Mol Biol. 2004;252:581–598. - PubMed